News
Sarepta shares slump on reports of third patient death this year
Shares of Sarepta Therapeutics declined 20% in early trading on Friday after media reports that a patient who had received one of its experimental gene therapies has died, deepening investor concern over the use of the company's treatments.
Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died ...
Second patient death from liver failure after Sarepta's Elevidys gene therapy triggers FDA investigation. Stock crashes 41% ...
The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...
GlobalData on MSN1d
Sarepta Therapeutics to cut 500 jobs amid restructuringThe company aims to focus on high-impact programmes to meet its 2027 financial obligations and support long-term viability.
The gene-therapy company is restructuring, laying off 36% of its workforce and making changes to its executive team.
In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...
These were the most active stocks ahead of Friday's market open: Sarepta Therapeutics Inc.'s stock tumbled 27% after the company said another patient died following gene-therapy treatment, Bloomberg ...
Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback